X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
glecaprevir (78) 78
pibrentasvir (76) 76
hepatitis c (40) 40
index medicus (40) 40
hepatitis c virus (37) 37
hcv (36) 36
sofosbuvir (32) 32
hepatitis (27) 27
gastroenterology & hepatology (25) 25
patients (22) 22
efficacy (21) 21
glecaprevir/pibrentasvir (20) 20
cirrhosis (19) 19
genotypes (19) 19
pharmacology & pharmacy (19) 19
safety (19) 19
antiviral agents (18) 18
velpatasvir (18) 18
ribavirin (17) 17
genotype (15) 15
infection (15) 15
infections (15) 15
interferon (15) 15
viruses (14) 14
health aspects (13) 13
medicine & public health (13) 13
direct-acting antivirals (12) 12
hepatology (12) 12
humans (12) 12
therapy (12) 12
genotype 1 (11) 11
chronic infection (10) 10
gastroenterology (10) 10
hcv genotype 1 (10) 10
hepatitis c, chronic - drug therapy (10) 10
ledipasvir (10) 10
medical research (10) 10
open-label (10) 10
antiretroviral drugs (9) 9
care and treatment (9) 9
clinical trials (9) 9
combination (9) 9
drug therapy, combination (9) 9
hemodialysis (9) 9
liver (9) 9
microbiology (9) 9
protease inhibitors (9) 9
sustained virologic response (9) 9
virus diseases (9) 9
virus genotype 1 (9) 9
6 infection (8) 8
antiviral agents - therapeutic use (8) 8
chronic hepatitis c (8) 8
colorectal surgery (8) 8
compensated cirrhosis (8) 8
daclatasvir (8) 8
direct-acting antiviral (8) 8
genotype & phenotype (8) 8
hepacivirus - genetics (8) 8
prevalence (8) 8
voxilaprevir (8) 8
abdominal surgery (7) 7
genetic aspects (7) 7
in-vitro (7) 7
infectious diseases (7) 7
liver cirrhosis (7) 7
liver diseases (7) 7
medicine, experimental (7) 7
medicine, general & internal (7) 7
retreatment (7) 7
surgical oncology (7) 7
treatment-naive (7) 7
asunaprevir (6) 6
benzimidazoles - therapeutic use (6) 6
drug therapy (6) 6
epidemiology (6) 6
hcv infection (6) 6
hepatitis-c virus (6) 6
hiv (6) 6
male (6) 6
middle aged (6) 6
pharmacokinetics (6) 6
proteases (6) 6
proteinase inhibitors (6) 6
public health (6) 6
quinoxalines - therapeutic use (6) 6
resistance (6) 6
sulfonamides - therapeutic use (6) 6
abt-493 (5) 5
adult (5) 5
aged (5) 5
analysis (5) 5
antiviral agents - administration & dosage (5) 5
antiviral drugs (5) 5
benzimidazoles - administration & dosage (5) 5
digestive system diseases (5) 5
drug combinations (5) 5
female (5) 5
fibrosis (5) 5
grazoprevir (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Internal Medicine, ISSN 0918-2918, 2019
Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs).... 
pibrentasvir | hemodialysis | HCV | retreatment | glecaprevir
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 03/2018, Volume 16, Issue 3, pp. 417 - 426
Hepatitis C virus (HCV) has high genotypic diversity and global distribution. Agents that are effective against all major HCV genotypes, with shorter treatment... 
Direct-acting Antiviral | Short-duration | DAA | Pangenotypic | GLECAPREVIR | VELPATASVIR | PIBRENTASVIR | NS5A | SOFOSBUVIR | ADULTS | HCV | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Internal Medicine, ISSN 0918-2918, 2019
The efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with human immunodeficiency virus (HIV) and/or genotype 3 hepatitis C virus (HCV)... 
hemophilia | HIV | pibrentasvir | HCV | genotype 3 | glecaprevir
Journal Article
JOURNAL OF GASTROENTEROLOGY, ISSN 0944-1174, 07/2019, Volume 54, Issue 7, pp. 660 - 666
BackgroundEfficacy of 8-week regimen with direct-acting antivirals (DAA) for patients with hepatitis C after liver transplantation has not been clarified. This... 
Pibrentasvir | INTERFERON-FREE THERAPY | SOFOSBUVIR | VIRUS GENOTYPE 1 | RIBAVIRIN | LEDIPASVIR | Glecaprevir | INCREASE | HCV | Hepatitis C | 6 INFECTION | GASTROENTEROLOGY & HEPATOLOGY | GLECAPREVIR/PIBRENTASVIR | Liver transplantation
Journal Article
JOURNAL OF GENERAL VIROLOGY, ISSN 0022-1317, 07/2019, Volume 100, Issue 7, pp. 1123 - 1131
Combination therapy with glecaprevir (GLE) and pibrentasvir (PIB) has high efficacy for pan-genotypic hepatitis C virus (HCV)-infected patients. However, the... 
ASUNAPREVIR | human hepatocyte chimeric mouse | RIBAVIRIN | NS5A inhibitor resistance associated variant | REPLICATION | VIROLOGY | pibrentasvir | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | HCV | DACLATASVIR | 6 INFECTION | ANTIVIRAL DRUGS | SOFOSBUVIR-VELPATASVIR | GLECAPREVIR/PIBRENTASVIR | glecaprevir
Journal Article
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, ISSN 1058-4838, 03/2019, Volume 69, Issue 10, pp. 1657 - 1664
Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated... 
Index Medicus | Major and Commentaries | chronic kidney disease | pibrentasvir | compensated cirrhosis | adverse event | HCV | glecaprevir
Journal Article
Journal of Hepatology, ISSN 0168-8278, 08/2018, Volume 69, Issue 2, pp. 293 - 300
Glecaprevir plus pibrentasvir (G/P) is a pangenotypic, once-daily, ribavirin-free direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV)... 
Short duration | Hepatitis C | Pangenotypic | Direct-acting antiviral | GLECAPREVIR | HEPATITIS-C VIRUS | EFFICACY | PIBRENTASVIR | SAFETY | INFECTION | FUTURE DISEASE BURDEN | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 4/2018, Volume 53, Issue 4, pp. 557 - 565
The once-daily, all oral, RBV-free, pangenotypic direct-acting anti-viral regimen consisting of co-formulated NS3/4A protease inhibitor glecaprevir and NS5A... 
Medicine & Public Health | Colorectal Surgery | Hepatology | Gastroenterology | Abdominal Surgery | Glecaprevir/pibrentasvir | Hepatitis C virus | Surgical Oncology | Direct-acting antivirals | ASIA | PHASE-3 TRIAL | RIBAVIRIN | COMPENSATED CIRRHOSIS | COMBINATION | GASTROENTEROLOGY & HEPATOLOGY | BURDEN | EPIDEMIOLOGY | Quinoxalines - adverse effects | Anilides - therapeutic use | Age Distribution | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Quinoxalines - blood | Sulfonamides - blood | Aged, 80 and over | Ritonavir - therapeutic use | Adult | Female | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - blood | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Drug Administration Schedule | Antiviral Agents - blood | Antiviral Agents - therapeutic use | Viral Nonstructural Proteins - genetics | Liver Cirrhosis - blood | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Macrocyclic Compounds - therapeutic use | Liver Cirrhosis - virology | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Aged | Sustained Virologic Response | Carbamates - therapeutic use | Drug Combinations | Virus diseases | Medical research | Protease inhibitors | Proteases | Medicine, Experimental | Genetic aspects | Health aspects | Liver cirrhosis | Cirrhosis | Antiviral agents | Ritonavir | Chronic infection | Proteinase inhibitors | Hepatitis C | Patients | Genotypes | Glecaprevir | pibrentasvir | Original —Liver, Pancreas, and Biliary Tract
Journal Article
International journal of antimicrobial agents, ISSN 0924-8579, 07/2019
This systematic review and meta-analysis investigated the efficacy and safety of glecaprevir and pibrentasvir (G/P) for chronic hepatitis C virus (HCV)... 
Journal Article
Gastroenterology & Hepatology, ISSN 1554-7914, 5/2019, Volume 15, Issue 5 Suppl 3, pp. 1 - 12
Elimination of hepatitis C virus (HCV) infection as a public health threat is a goal of the World Health Organization. Official treatment guidelines are... 
sofosbuvir | pibrentasvir | Column | velpatasvir | simplified treatment | Hepatitis C | glecaprevir
Journal Article
Australian prescriber, ISSN 0312-8008, 10/2018, Volume 41, Issue 5, pp. 169 - 170
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.